Today's Low
₹ 4,567.05
Today's High
₹ 4,644.95
52 Weeks Low
₹ 2,828.00
52 Weeks High
₹ 3,625.00
Lower
₹ 4,185.80
Upper
₹ 5,115.90
Alkem Laboratories Limited, a pharmaceutical company, develops, manufactures, and sells pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, diabetology, cardiology, gastroenterology, osteoporosis, central nervous system, oncology, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain relief/analgesic, anti-diabetic, and neurology products. It also provides pregnancy detection kits and condoms. Alkem Laboratories Limited was incorporated in 1973 and is headquartered in Mumbai, India.
No Data Found
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 8,606.4 | 8,433.7 | 6,923.3 | 5,505.7 | 4,204.4 | 4,013.2 | 2,917.1 | 2,768.7 | 2,338.1 | 1,602.1 | 2,156.2 | 1,312.3 | 1,538.6 |
Total Non-Current Assets | 3,724.5 | 4,324.5 | 3,482.5 | 3,507.3 | 3,284.4 | 2,996.8 | 2,954.6 | 2,249.7 | 2,953.2 | 2,709.3 | 2,114.6 | 2,153.4 | 1,313.2 |
Total Assets | 12,454.1 | 12,759.9 | 10,411.4 | 9,013.0 | 7,500.6 | 7,010.0 | 5,871.8 | 5,018.4 | 5,291.3 | 4,311.5 | 4,270.8 | 3,465.7 | 2,851.8 |
Total Current Liabilities | 3,707.1 | 4,805.3 | 3,604.1 | 3,244.6 | 2,217.5 | 2,383.3 | 1,689.7 | 1,537.6 | 2,006.0 | 1,402.6 | 1,731.8 | 1,120.6 | 981.9 |
Total Non-Current Liabilities | -688.0 | -892.7 | -750.7 | -540.6 | -288.9 | -358.6 | -400.8 | -306.2 | 200.6 | 323.9 | 361.7 | 524.9 | 434.4 |
Shareholder's Funds | 9,045.3 | 8,637.9 | 7,376.7 | 6,160.7 | 5,439.3 | 4,863.8 | 4,467.6 | 3,692.0 | 2,999.1 | 2,585.0 | 2,177.3 | 1,820.1 | 1,433.7 |
Total Liabilities | 12,454.1 | 12,759.9 | 10,411.4 | 9,013.0 | 7,500.6 | 7,010.0 | 5,871.8 | 5,018.4 | 5,291.3 | 4,311.5 | 4,270.8 | 3,465.7 | 2,851.8 |
The Industry Quick Ratio stands at 1.60, vs the Quick Ratio of 1.13, which results in a Negative aspect.
The Industry Debt to Equity Ratio stands at 0.22, vs the Debt to Equity Ratio of 0.26, which results in a Negative aspect.
The Industry Price to BV stands at 6.08, vs the Price to BV of 5.32, which results in a Negative aspect.
The Industry Current Ratio stands at 2.31, vs the Current Ratio of 1.69, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Income | 11,599.3 | 10,634.2 | 8,865.0 | 8,344.4 | 7,357.2 | 6,391.8 | 5,687.5 | 4,924.8 | 3,743.4 | 3,126.0 | 2,495.2 | 2,015.6 | 1,690.8 |
Total Expenditure | 9,989.8 | 8,581.3 | 6,922.6 | 6,871.0 | 6,242.4 | 5,382.9 | 4,688.6 | 4,071.6 | 3,321.5 | 2,716.1 | 2,132.8 | 1,640.4 | 1,404.2 |
Operating Profit(Excl OI) | 1,825.5 | 2,215.6 | 2,175.6 | 1,577.6 | 1,202.5 | 1,124.3 | 1,111.0 | 1,093.0 | 602.9 | 575.3 | 529.6 | 520.5 | 400.0 |
Add: Other Income | 216.1 | 162.7 | 233.2 | 104.2 | 87.7 | 115.4 | 112.0 | 239.7 | 181.0 | 165.4 | 167.2 | 145.3 | 113.4 |
Operating Profit | 1,825.5 | 2,215.6 | 2,175.6 | 1,577.6 | 1,202.5 | 1,124.3 | 1,111.0 | 1,093.0 | 602.9 | 575.3 | 529.6 | 520.5 | 400.0 |
Less: Interest | 107.4 | 52.4 | 58.9 | 65.1 | 54.6 | 55.3 | 45.2 | 71.2 | 81.1 | 93.1 | 88.2 | 58.1 | 41.2 |
PBDT | 1,718.2 | 2,163.2 | 2,116.7 | 1,512.6 | 1,147.8 | 1,069.0 | 1,065.8 | 1,021.7 | 521.8 | 482.2 | 441.4 | 462.4 | 358.8 |
Less: Depreciation Amortization | 310.4 | 304.0 | 274.6 | 252.8 | 193.2 | 143.0 | 101.2 | 93.3 | 70.9 | 52.3 | 39.8 | 29.0 | 27.4 |
PBT & Exceptional Items | 1,407.8 | 1,859.2 | 1,842.1 | 1,259.8 | 954.7 | 926.0 | 964.6 | 928.4 | 450.8 | 430.0 | 401.6 | 433.4 | 331.4 |
Less: Exceptional Income Expenses | -103.0 | -15.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit Before Tax | 1,304.8 | 1,844.3 | 1,842.1 | 1,259.8 | 954.7 | 926.0 | 964.6 | 928.4 | 450.8 | 430.0 | 401.6 | 433.4 | 331.4 |
Less: Taxation | 298.0 | 164.0 | 224.3 | 110.5 | 181.0 | 287.6 | 60.0 | 176.2 | 59.2 | -5.4 | 18.0 | 27.5 | 35.6 |
Profit After Tax | 1,006.8 | 1,680.3 | 1,617.8 | 1,149.3 | 773.6 | 638.4 | 904.7 | 752.2 | 391.6 | 435.3 | 383.6 | 405.8 | 295.8 |
Earnings Per Share | 8.2 | 13.8 | 13.3 | 9.4 | 6.4 | 5.3 | 7.5 | 6.2 | 3.3 | 3.6 | 3.2 | 3.4 | 2.5 |
The Industry PAT Margin stands at 9.73, vs the PAT Margin of 9.27, which results in a Negative aspect.
The Industry PE Ratio stands at 43.11, vs the PE Ratio of 35.33, which results in a Negative aspect.
The Industry PAT Growth stands at 32.10, vs the PAT Growth of 48.56, which results in a Positive aspect.
The Industry Dividend Yield stands at 0.59, vs the Dividend Yield of 1.08, which results in a Positive aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit Before Tax | 1,304.8 | 1,844.3 | 1,842.1 | 1,259.8 | 954.7 | 926.0 | 964.6 | 928.4 | 450.8 | 430.0 | 401.6 | 433.4 |
Tax Paid | -273.4 | -396.9 | -400.7 | -283.4 | -251.1 | -203.2 | -264.0 | -198.2 | -105.6 | -111.1 | -110.2 | -96.6 |
Adjustment | 324.4 | 208.6 | 164.6 | 255.9 | 216.4 | 116.5 | 33.0 | -14.4 | -7.8 | 7.5 | -30.6 | -32.9 |
Changes In Working Capital | 1,304.8 | 1,844.3 | 1,842.1 | 1,259.8 | 954.7 | 926.0 | 964.6 | 928.4 | 450.8 | 430.0 | 401.6 | 433.4 |
Cash Flow after changes in Working Capital | 1,955.9 | 1,507.9 | 1,665.6 | 868.5 | 1,030.8 | 469.2 | 735.1 | 924.0 | 431.1 | 401.1 | 188.3 | 255.7 |
Cash Flow from Operating Activities | 1,682.5 | 1,111.0 | 1,264.9 | 585.1 | 779.7 | 266.0 | 471.1 | 725.8 | 325.5 | 290.0 | 78.1 | 159.1 |
Cash Flow from Investing Activities | 112.8 | -1,435.1 | -998.5 | -741.4 | -316.4 | -357.2 | -285.9 | 202.3 | -237.0 | 350.4 | -403.5 | -247.5 |
Cash Flow from Financing Activities | -1,760.8 | 379.6 | -271.8 | 79.2 | -378.9 | 84.6 | -137.9 | -927.3 | -51.8 | -599.9 | 355.6 | -11.1 |
Net Cash Inflow / Outflow | 34.5 | 55.5 | -5.4 | -77.1 | 84.3 | -6.6 | 47.3 | 0.8 | 36.7 | 40.5 | 30.2 | -99.5 |
Opening Cash & Cash Equivalents | 232.2 | 174.2 | 175.9 | 249.1 | 166.7 | 166.6 | 127.0 | 123.8 | 100.8 | 57.3 | 26.4 | 124.0 |
Closing Cash & Cash Equivalent | 273.8 | 232.2 | 174.2 | 175.9 | 249.1 | 166.7 | 166.6 | 127.1 | 139.6 | 100.8 | 57.3 | 26.4 |
The Industry PFCF Ratio stands at 25.12, vs the PFCF Ratio of 71.06, which results in a Positive aspect.
The Industry PCF RATIO stands at 24.27, vs the PCF RATIO of 47.59, which results in a Positive aspect.
Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 33,238.7 | 34,401.7 | 29,677.2 | 29,026.0 | 30,409.1 | 30,793.7 | 25,763.8 | 24,838.6 | 26,189.8 | 27,999.9 | 27,313.6 | 21,921.6 | 23,180.5 | 23,628.0 | 20,034.9 | 20,489.9 |
Total Income | 34,175.1 | 35,033.6 | 30,335.6 | 29,712.7 | 30,862.4 | 31,300.4 | 26,277.9 | 25,043.8 | 26,725.0 | 28,419.5 | 27,780.1 | 22,384.4 | 24,144.5 | 23,983.4 | 20,469.9 | 20,764.6 |
Total Expenditure | 26,162.8 | 26,934.4 | 25,785.3 | 25,493.5 | 24,418.6 | 26,254.6 | 23,731.4 | 21,466.3 | 21,205.3 | 21,756.1 | 21,385.0 | 19,010.6 | 17,889.4 | 17,623.1 | 14,703.1 | 17,459.6 |
PBIDT (Excl OI) | 7,075.9 | 7,467.3 | 3,891.9 | 3,532.5 | 5,990.5 | 4,539.1 | 2,032.4 | 3,372.3 | 4,984.5 | 6,243.8 | 5,928.6 | 2,911.0 | 5,291.1 | 6,004.9 | 5,331.8 | 3,030.3 |
Other Income | 936.4 | 631.9 | 658.4 | 686.7 | 453.3 | 506.7 | 514.1 | 205.2 | 535.2 | 419.6 | 466.5 | 462.8 | 964.0 | 355.4 | 435.0 | 274.7 |
Operating Profit | 8,012.3 | 8,099.2 | 4,550.3 | 4,219.2 | 6,443.8 | 5,045.8 | 2,546.5 | 3,577.5 | 5,519.7 | 6,663.4 | 6,395.1 | 3,373.8 | 6,255.1 | 6,360.3 | 5,766.8 | 3,305.0 |
Interest | 254.6 | 303.2 | 297.7 | 289.6 | 270.5 | 248.5 | 265.0 | 169.7 | 105.7 | 119.7 | 128.6 | 107.1 | 130.7 | 180.4 | 171.0 | 141.5 |
Exceptional Items | -513.1 | -576.6 | 0.0 | -1,029.8 | 0.0 | 0.0 | 0.0 | -149.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
PBDT | 7,244.6 | 7,219.4 | 4,252.6 | 2,899.8 | 6,173.3 | 4,797.3 | 2,281.5 | 3,258.2 | 5,414.0 | 6,543.7 | 6,266.5 | 3,266.7 | 6,124.4 | 6,179.9 | 5,595.8 | 3,163.5 |
Depreciation | 695.6 | 739.0 | 724.1 | 783.2 | 784.4 | 774.0 | 762.6 | 831.4 | 774.6 | 728.3 | 705.3 | 685.1 | 690.0 | 702.4 | 668.3 | 810.5 |
Profit Before Tax | 6,549.0 | 6,480.4 | 3,528.5 | 2,116.6 | 5,388.9 | 4,023.3 | 1,518.9 | 2,426.8 | 4,639.4 | 5,815.4 | 5,561.2 | 2,581.6 | 5,434.4 | 5,477.5 | 4,927.5 | 2,353.0 |
Tax | 506.2 | 331.5 | 650.4 | 1,439.8 | 789.3 | 546.1 | 204.4 | 1,344.7 | -694.1 | 230.1 | 758.9 | 89.4 | 795.9 | 662.4 | 695.6 | 437.6 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | 6,042.8 | 6,148.9 | 2,878.1 | 676.8 | 4,599.6 | 3,477.2 | 1,314.5 | 1,082.1 | 5,333.5 | 5,585.3 | 4,802.3 | 2,492.2 | 4,638.5 | 4,815.1 | 4,231.9 | 1,915.4 |
Net Profit | 6,042.8 | 6,148.9 | 2,878.1 | 676.8 | 4,599.6 | 3,477.2 | 1,314.5 | 1,082.1 | 5,333.5 | 5,585.3 | 4,802.3 | 2,492.2 | 4,638.5 | 4,815.1 | 4,231.9 | 1,915.4 |
ADDITIONAL INFOS: | ||||||||||||||||
Equity Capital | 239.1 | 239.1 | 239.1 | 239.1 | 239.1 | 239.1 | 239.1 | 239.1 | 239.1 | 239.1 | 239.1 | 239.1 | 239.1 | 239.1 | 239.1 | 239.1 |
Reserves | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
EPS | 49.8 | 51.9 | 24.0 | 5.9 | 38.0 | 27.7 | 10.7 | 9.0 | 44.0 | 45.5 | 39.2 | 20.1 | 37.7 | 39.5 | 35.3 | 15.8 |
Operating Profit Margin | 24.1 | 23.5 | 15.3 | 14.5 | 21.2 | 16.4 | 9.9 | 14.4 | 21.1 | 23.8 | 23.4 | 15.4 | 27.0 | 26.9 | 28.8 | 16.1 |
Net Profit Margin | 18.2 | 17.9 | 9.7 | 2.3 | 15.1 | 11.3 | 5.1 | 4.4 | 20.4 | 19.9 | 17.6 | 11.4 | 20.0 | 20.4 | 21.1 | 9.3 |
The Industry Net Sales Growth stands at 11.07, vs the Net Sales Growth of 13.42, which results in a Positive aspect.
The Industry Mcap Growth stands at 19.65, vs the Mcap Growth of 32.94, which results in a Positive aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 4,772.15 | 4,844.88 | 4,659.20 |
R3 | 4,729.75 | 4,733.20 | 4,637.77 |
R2 | 4,687.35 | 4,689.08 | 4,630.63 |
R1 | 4,651.85 | 4,655.30 | 4,623.49 |
Pivot | 4,609.45 | 4,611.18 | 4,609.45 |
S1 | 4,573.95 | 4,577.40 | 4,609.21 |
S2 | 4,531.55 | 4,533.28 | 4,602.07 |
S3 | 4,496.05 | 4,499.50 | 4,594.93 |
S4 | 4,460.55 | 4,377.48 | 4,573.51 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
0.00
Bullish
RSI
33.07
Neutral
ROC
-6.84
Bearish
UltimateOscillator
37.24
Neutral
Williams Indicator
-90.66
Bullish
CCI Indicator
-146.70
Bullish
MACD
682.60
Bullish
Stochastic Indicator
7.28
Bullish
ATR
135.90
High Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|---|---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|---|---|---|
16-02-2024 | 35.00 | 1750 | Interim |
10-08-2023 | 10.00 | 500 | Final |
17-02-2023 | 25.00 | 1250 | Special |
17-02-2023 | 15.00 | 750 | Interim |
08-08-2022 | 4.00 | 200 | Final |
10-02-2022 | 30.00 | 1500 | Interim |
09-08-2021 | 5.00 | 250 | Final |
Date Of Conduct | Board Meeting Details |
---|---|
09-02-2024 | Interim Dividend & Quarterly Results |
07-11-2023 | Quarterly Results |
10-08-2023 | Quarterly Results |
19-05-2023 | Final Dividend & Audited Results |
10-02-2023 | Quarterly Results & Interim Dividend |
11-11-2022 | Quarterly Results |
05-08-2022 | Quarterly Results |
13-05-2022 | Audited Results & Final Dividend |
04-02-2022 | Interim Dividend & Quarterly Results |
12-11-2021 | Quarterly Results |
06-08-2021 | Quarterly Results |
25-05-2021 | Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2021 ,inter alia, to consider and approve (i) to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2021; and (ii) to consider and recommend Final Dividend, if any, for the financial year ended 31st March, 2021. Kindly take note of the same. |